150 related articles for article (PubMed ID: 33884929)
1. Comparison of weekly and daily recall of pain as an endpoint in a randomized phase 3 trial of cabozantinib for metastatic castration-resistant prostate cancer.
Schaffer EM; Basch EM; Schwab GM; Bennett AV
Clin Trials; 2021 Aug; 18(4):408-416. PubMed ID: 33884929
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint.
Basch EM; Scholz M; de Bono JS; Vogelzang N; de Souza P; Marx G; Vaishampayan U; George S; Schwarz JK; Antonarakis ES; O'Sullivan JM; Kalebasty AR; Chi KN; Dreicer R; Hutson TE; Dueck AC; Bennett AV; Dayan E; Mangeshkar M; Holland J; Weitzman AL; Scher HI
Eur Urol; 2019 Jun; 75(6):929-937. PubMed ID: 30528222
[TBL] [Abstract][Full Text] [Related]
3. Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
Basch E; Autio KA; Smith MR; Bennett AV; Weitzman AL; Scheffold C; Sweeney C; Rathkopf DE; Smith DC; George DJ; Higano CS; Harzstark AL; Sartor AO; Gordon MS; Vogelzang NJ; de Bono JS; Haas NB; Corn PG; Schimmoller F; Scher HI
Eur Urol; 2015 Feb; 67(2):310-8. PubMed ID: 24631409
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials.
Sonpavde GP; Pond GR; Fizazi K; de Bono JS; Basch EM; Scher HI; Smith MR
Eur Urol Oncol; 2020 Aug; 3(4):540-543. PubMed ID: 31412002
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.
Smith DC; Daignault-Newton S; Grivas P; Reichert ZR; Hussain M; Cooney KA; Caram M; Alva A; Jacobson J; Yablon C; Mehra R; Escara-Wilke J; Shelley G; Keller ET
Clin Genitourin Cancer; 2020 Aug; 18(4):332-339.e2. PubMed ID: 32299729
[TBL] [Abstract][Full Text] [Related]
6. Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
Leibowitz-Amit R; Pintilie M; Khoja L; Azad AA; Berger R; Laird AD; Aftab DT; Chi KN; Joshua AM
J Transl Med; 2016 Jan; 14():12. PubMed ID: 26762579
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Smith MR; Sweeney CJ; Corn PG; Rathkopf DE; Smith DC; Hussain M; George DJ; Higano CS; Harzstark AL; Sartor AO; Vogelzang NJ; Gordon MS; de Bono JS; Haas NB; Logothetis CJ; Elfiky A; Scheffold C; Laird AD; Schimmoller F; Basch EM; Scher HI
J Clin Oncol; 2014 Oct; 32(30):3391-9. PubMed ID: 25225437
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer: cabozantinib reduces pain and narcotic use in men with CRPC.
Clyne M
Nat Rev Urol; 2014 Apr; 11(4):188. PubMed ID: 24619377
[No Abstract] [Full Text] [Related]
9. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.
Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C
Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621
[TBL] [Abstract][Full Text] [Related]
11. Current role of cabozantinib in metastatic castration-resistant prostate cancer.
Fay AP; Albiges L; Bellmunt J
Expert Rev Anticancer Ther; 2015 Feb; 15(2):151-6. PubMed ID: 25586337
[TBL] [Abstract][Full Text] [Related]
12. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
Smith M; De Bono J; Sternberg C; Le Moulec S; Oudard S; De Giorgi U; Krainer M; Bergman A; Hoelzer W; De Wit R; Bögemann M; Saad F; Cruciani G; Thiery-Vuillemin A; Feyerabend S; Miller K; Houédé N; Hussain S; Lam E; Polikoff J; Stenzl A; Mainwaring P; Ramies D; Hessel C; Weitzman A; Fizazi K
J Clin Oncol; 2016 Sep; 34(25):3005-13. PubMed ID: 27400947
[TBL] [Abstract][Full Text] [Related]
13. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
Pinto A
Cancer Chemother Pharmacol; 2014 Feb; 73(2):219-22. PubMed ID: 24202668
[TBL] [Abstract][Full Text] [Related]
15. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
16. Comparison of daily and weekly retrospectively reported pain intensity in patients with localized and generalized musculoskeletal pain.
Giske L; Sandvik L; Røe C
Eur J Pain; 2010 Oct; 14(9):959-65. PubMed ID: 20363653
[TBL] [Abstract][Full Text] [Related]
17. Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer.
Di Nunno V; Cimadamore A; Santoni M; Scarpelli M; Fiorentino M; Ciccarese C; Iacovelli R; Cheng L; Lopez-Beltran A; Massari F; Montironi R
Future Oncol; 2018 Oct; 14(25):2559-2564. PubMed ID: 30141348
[No Abstract] [Full Text] [Related]
18. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND
Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
[TBL] [Abstract][Full Text] [Related]
20. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Fizazi K; Massard C; Bono P; Jones R; Kataja V; James N; Garcia JA; Protheroe A; Tammela TL; Elliott T; Mattila L; Aspegren J; Vuorela A; Langmuir P; Mustonen M;
Lancet Oncol; 2014 Aug; 15(9):975-85. PubMed ID: 24974051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]